Industry News

Argos Therapeutics Inc., an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis ® technology platform, today announced that the company will be presenting at the 2016 BIO Investor Forum to be held October 18-19 at the Westin St. Francis Hotel in San Francisco, California.. Richard Katz, MD, chief financial officer of Argos, will present on Wednesday, October 19 at 11:30am PT in..."/>
Argos Therapeutics to Participate in 2016 BIO Investor Forum
Cardiome Pharma Corp. announced that it has initiated commercial sales operations in Canada. The Canadian sales force will immediately begin detailing AGGRASTAT ® to Canadian hospitals but is expected to expand its efforts to include the detailing of BRINAVESS ®, XYDALBA™ and TREVYENT ®, if and when marketing approval for each respective drug is granted by Health Canada's Therapeutic Products Directorate. Commenting on the initiation of..."/>
Cardiome Announces Initiation of Commercial Operations in Canada, Eh
Incyte Corporation announced today that it has scheduled its third quarter 2016 financial results conference call and webcast for 10:00 a.m. ET on Tuesday, November 1, 2016.. The schedule for the press release and conference call/webcast is as follows:. If you are unable to participate, a replay of the conference call will be available for thirty days."/>
Incyte to Report Third Quarter Financial Results
Allergan plc, a leading global pharmaceutical company committed to the research and development of new treatments for gastrointestinal diseases, today announced that new data from its irritable bowel syndrome portfolio will be featured in two poster presentations at the upcoming American College of Gastroenterology Annual Scientific Meeting in Las Vegas, NV, October 14-19, 2016.. The scheduled times of the three VIBERZI ® presentations..."/>
Allergan Demonstrates Continued Commitment to Irritable Bowel Syndrome with Diarrhea Management with Two Poster Presentations at ACG 2016
Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, today announced that the European Medicines Agency’ s Committee for Medicinal Products for Human Use adopted a positive opinion recommending marketing authorization of the Company’ s Marketing Authorization Application for obeticholic acid, an FXR agonist, for the..."/>
Intercept Pharmaceuticals Receives Positive CHMP Opinion for Ocaliva® (Obeticholic Acid) for the Treatment of Primary Biliary Cholangitis in the European Union
Tetraphase Pharmaceuticals, Inc. today announced dosing of the first patient in IGNITE4, the Company’ s phase 3 clinical trial evaluating the efficacy and safety of intravenous eravacycline compared to meropenem in complicated intra-abdominal infections."/>
Tetraphase Pharmaceuticals Doses First Patient in IGNITE4 Phase 3 Clinical Trial of Eravacycline in cIAI
Alimera Sciences Inc., Biostar Pharmaceuticals Inc., LifePoint Health Inc., and Quorum Health Corp.. These companies belong to the Healthcare sector which ended moderately higher on Thursday, October 13, 2016."/>
Research Reports Initiation on Healthcare Stocks -- Alimera Sciences, Biostar Pharma, LifePoint Health, and Quorum Health
Kite Pharma revealed on Thursday the addition of Chris Nowers as head of Europe. Based in London, Nowers will be responsible for the company' s European commercial operations, build awareness in the region of its growing pipeline portfolio of chimeric antigen receptor and T-cell receptor therapy product candidates as well as prepare for the potential launch of its lead product candidate, KTE-C19. Most recently, Nowers has worked in senior..."/>
Kite Pharma names Chris Nowers head of Europe
WellCare Health Plans Inc reported on Thursday the appointment of Elizabeth Miller as state president, Florida,. Effective 15 October 2016, Miller will be responsible for the company's Medicaid and Medicare Advantage businesses across the state, including strategy, regulatory compliance, network management, sales and marketing, medical management, finance and administration. She will report to the outgoing Gregg MacDonald, who has been named as its..."/>
WellCare elects Elizabeth Miller as state president, Florida
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing gene therapies for life-threatening rare diseases, announced today that top-line results of the low-dose cohort for ABO-102 in Phase 1/ 2 clinical trial for Sanfilippo type A patients will be presented at the Orphan Drugs and Rare Disease Congress taking place in London, UK, from October 19 th through October 20 th. The company's ABO-102 program,..."/>
Abeona Therapeutics to Present Top-Line Data of Low-Dose Cohort for ABO-102 in Phase 1/2 Clinical Trial for MPS IIIA Patients at Upcoming Orphan Drugs and Rare Disease Congress October 19-20th in London, UK
Adverum Biotechnologies, Inc. today provided an update on its development program for ADVM-043, a novel gene therapy for Alpha-1 Antitrypsin Deficiency, a rare genetic disorder that may result in serious respiratory and liver disease. Adverum has decided to upgrade the ADVM-043 manufacturing process by implementing its proprietary baculovirus-based production system and plans to transfer the third-party contract manufacturing for..."/>
Adverum Biotechnologies Provides Update on Alpha-1 Antitrypsin Deficiency Program
Adverum Biotechnologies, Inc., a gene therapy company committed to discovering and developing novel medicines for patients suffering from diseases with few or burdensome treatment options, today announced that former Chief Executive Officer Paul B. Cleveland has been appointed Executive Chairman of the Board and that Amber Salzman, Ph.D., formerly President and Chief Operating Officer, has..."/>
Adverum Biotechnologies, Inc. Announces New Executive Chair and CEO
CytoSorbents Corporation, a critical care immunotherapy leader commercializing its flagship CytoSorb ® extracorporeal cytokine adsorber to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that CEO Dr. Phillip Chan, MD, PhD, will present at the 2016 BIO Investor Forum taking place October 18-19, 2016 in San Francisco. A live webcast of the presentation will be available..."/>
CytoSorbents to Present at the 2016 BIO Investor Forum
Akari Therapeutics, an emerging growth, clinical-stage biopharmaceutical company, announced today the appointment of Robert Ward to its Board of Directors. Ward brings over twenty-five years of pharmaceutical experience to the Board and follows recent Board appointee Donald Williams who was elected to the Board in June 2016. Akari also announced that Mark Cohen has stepped down from the Board in order to serve as outside counsel to Akari on US..."/>
Akari Therapeutics Appoints New Members to its Board of Directors
Intellia Therapeutics, Inc., a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that members of its scientific team will present new data at the European Society of Gene& Cell Therapy Congress in Florence, Italy from October 18-21, 2016. Abstracts will be available online at on October 17, 2016.. “The data being presented at ESGCT show Intellia’ s..."/>
Intellia Therapeutics to Present Data at the European Society of Gene & Cell Therapy Congress
Allergan plc.. RTGel™ has thermo-sensitive properties that enable it to convert from a liquid state when cold, into a gel once it reaches body temperature. This allows increased residence time of drugs when mixed with the gel..."/>
UroGen Pharma Announces Agreement to License RTGel™ for Use with Neurotoxins to Allergan
Universal American Corp. announced gains in Medicare Star Quality for 2017 as published by the Centers for Medicare& Medicaid Services."/>
Universal American Announces 2017 Medicare Star Ratings
MEDNAX, Inc., will host an investor conference call and webcast on Thursday, October 27, 2016 at 11:00 a.m. EDT, to discuss results from operations for the quarter and the nine months ended September 30, 2016. A detailed press release will be issued the morning of October 27, 2016 before the securities markets open. The investor conference call will be webcast and can be accessed at MEDNAX’ s website,"/>
MEDNAX 2016 Third Quarter Conference Call/Webcast Scheduled for Thursday, October 27, 2016
OraSure Technologies, Inc. today announced that its 2017 Annual Meeting of Stockholders is scheduled to be held at 10:00 a.m. EDT on Tuesday, May 16, 2017. This will be a completely virtual meeting, conducted as a live webcast. Further details regarding the meeting will be provided at a later date.."/>
OraSure Technologies Announces 2017 Annual Meeting Date
BAXTER and ASPEN, show nearly 2 million U.S. hospital stays1 involve malnutrition. -Malnutrition-related hospital stays have up to a five times higher risk of deaths2, compared to patient stays not identified as malnourished. -Most malnourished-related hospital stays were two times longer1 than for patient stays not identified as malnourished."/>
New Data Show Malnutrition in U.S. Hospitals Associated with a $42 Billion Burden to Health System
Astellas Pharma Inc. today announced a global agreement to partner on the prevention of misuse and abuse of medicines for doping in sports. Doping in sports relies primarily on the misuse and abuse of commercially available medicines, as well as compounds in development that are not as well-known or easily detected."/>
World Anti-Doping Agency and Astellas Announce Global Initiative to Prevent Misuse and Abuse of Medicines for Doping in Sports
BTG plc, an international specialist healthcare company, with Mirada Medical Ltd, a leading global brand in medical imaging software, today announced CE Mark certification for Simplicit 90 Y™ dosimetry software, designed to optimise the planning of 90 Y selective internal radiation therapy and..."/>
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y™ Dosimetry Software in Europe

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology699 Articles
Consumer Discretionary669 Articles
Financials612 Articles
Industrials447 Articles
Health Care441 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at